GLP1R and diabetes mellitus: An increasing number of patients with type 2 diabetes mellitus (T2DM) are being treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a new class of anti-diabetic agents based on incretin therapy[1, 2].